Skip to main navigation Skip to search Skip to main content

Astegolimab or Efmarodocokin Alfa in Patients with Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial∗

  • Michael Waters
  • , James A. McKinnell
  • , Andre C. Kalil
  • , Greg S. Martin
  • , Timothy G. Buchman
  • , Wiebke Theess
  • , Xiaoying Yang
  • , Annemarie N. Lekkerkerker
  • , Tracy Staton
  • , Carrie M. Rosenberger
  • , Rajita Pappu
  • , Yehong Wang
  • , Wenhui Zhang
  • , Logan Brooks
  • , Dorothy Cheung
  • , Joshua Galanter
  • , Hubert Chen
  • , Divya Mohan
  • , Melicent C. Peck*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Astegolimab or Efmarodocokin Alfa in Patients with Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial∗'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology